Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health
New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com
Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

SAP badge AJMC
February 14th 2022

From Our Partners: Schleicher, Dickson Take New Roles at Tennessee Oncology

Hayden E. Klein Mary Caffrey
The changes come as Tennessee Oncology must now plan for a gap between the Oncology Care Model and a future alternative payment model from CMS.
What We're Reading
February 2nd 2022

What We’re Reading: Cancer Moonshot Returns; New Omicron Subvariant; Drug Overdose Suicide Rates

AJMC Staff
President Biden announced he would bring back the Cancer Moonshot initiative that launched in the Obama administration; the World Health Organization said the Omicron subvariant, BA.2, appears to have the same severity as the original Omicron variant; cases of suicide by drug overdose increased in young people, older adults, and non-Hispanic Black women.
COA Survey: Practices Find OCM a Success; Some Added Services May Be at Risk
January 31st 2022

COA Survey: Practices Find OCM a Success; Some Added Services May Be at Risk

Mary Caffrey
The Oncology Care Model (OCM) is set to expire June 30, 2022. With no successor on the horizon, respondents to a recent survey by the Community Oncology Alliance (COA) say features such as dedicated navigators and weekend appointments could be reduced or lost if revenues that supported them are eliminated.
Site Logo
January 11th 2022

Management of TRK Fusion Cancer: Evaluating Targeted Therapies - Participating Faculty

Site Logo
January 11th 2022

Diagnosis and Management of TRK Fusion Cancer

Shivaani Kummar, MD, FACP Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Josh J. Carlson, PhD, MPH Sean D. Sullivan, PhD, MSc, RPh Ulrik Lassen, MD, PhD Noah Federman, MD
Site Logo
January 11th 2022

Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

Josh J. Carlson, PhD, MPH Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Noah Federman, MD Ulrik Lassen, MD, PhD Shivaani Kummar, MD, FACP Sean D. Sullivan, PhD, MSc, RPh
Stephen Schleicher, MD, MBA
January 3rd 2022

Tennessee Oncology Names Dr Stephen Schleicher CMO, Dr Natalie Dickson CSO

Hayden E. Klein
Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).
Burt Zweigenhaft, PhD, DLitt, Upstream Partners
December 20th 2021

CONFERENCE COVERAGE: Asembia 2021

Matthew Gavidia
Coverage from the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.
PCOC Spotlight: There’s Been a Lot of Good for Patients With the OCM, Says US Oncology’s Neubauer
December 20th 2021

PCOC Spotlight: There’s Been a Lot of Good for Patients With the OCM, Says US Oncology’s Neubauer

Laura Joszt, MA
Marcus Neubauer, MD, chief medical officer, The US Oncology Network. He is an expert in precision medicine, value-based care, and clinical pathways.
PCOC Spotlight: How Community Oncology Is a Low-Cost, High-Quality Provider
December 20th 2021

PCOC Spotlight: How Community Oncology Is a Low-Cost, High-Quality Provider

Laura Joszt, MA
Jeffrey Patton, MD, is the CEO of OneOncology, a national partnership of independent community oncologists based in Nashville, Tennessee. He is also executive chairman of the board, Tennessee Oncology, and a member of the board, Community Oncology Alliance.
In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract
December 20th 2021

In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract

Mary Caffrey
Vertical integration of payers and pharmacy benefit managers (PBMs) took flight with the mergers of Aetna and CVS Health and of Cigna and ExpressScripts. Panelists at Patient-Centered Oncology Care® said the shift has filtered down to affect access at the practice level.
Panel Discusses the Ongoing Evolution of Remote Patient Care
December 19th 2021

Panel Discusses the Ongoing Evolution of Remote Patient Care

Maggie L. Shaw
The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.
PCOC SPOTLIGHT: In Taking on Disparities, What Is Actionable? What Can We Share With the Nation?
December 19th 2021

PCOC SPOTLIGHT: In Taking on Disparities, What Is Actionable? What Can We Share With the Nation?

Laura Joszt, MA
Karen Winkfield, MD, PhD, is the executive director of the Meharry-Vanderbilt Alliance, a strategic partnership between Meharry Medical College and Vanderbilt College of Medicine, Nashville, Tennessee. She is also Ingram Professor of Cancer Research and professor of radiation oncology, Vanderbilt-Ingram Cancer Center.
PCOC SPOTLIGHT: Patel Says Let the OCM Continue for Now
December 19th 2021

PCOC SPOTLIGHT: Patel Says Let the OCM Continue for Now

Laura Joszt, MA
The Oncology Care Model (OCM) is scheduled to end in just a few months, but with no new model in place to succeed it and practices still struggling during the pandemic, CMS should allow OCM to continue, said Kashyap Patel, MD, a co-chair of Patient-Centered Oncology Care® and the current president of the Community Oncology Alliance. He is CEO of Carolina Blood and Cancer Care Associates.
PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology
December 19th 2021

PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology

Allison Inserro
Joseph Alvarnas, MD, a co-chair of Patient-Centered Oncology Care® (PCOC), discussed the unique nature of PCOC and what it offers for providers, payers, policy leaders, and technology experts who take part. Alvarnas is vice president, Government Affairs; senior medical director, employer strategy, and clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope.
Surveys Probe Biosimilars in Oncology
December 13th 2021

Surveys Probe Biosimilars in Oncology

Tony Hagen
Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.
Site Logo
December 9th 2021

Mental Health Distress Impacting Cancer Patients, Says New Cardinal Health Survey of Oncologists

More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.
Kathleen Maignan, MSN, NP
December 8th 2021

Flatiron Health Leverages Expertise With Real-World Data to Examine Cancer Care Disparities

Mary Caffrey
Physician and patient.
November 23rd 2021

Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics

Matthew Gavidia
Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.
Karen van Caulil, PhD
November 22nd 2021

Dr Karen van Caulil: End of Oncology Care Model Could Leave Gap in Comprehensive Care

Hayden E. Klein
Karen L. van Caulil, PhD, president and CEO of Florida Alliance for Healthcare Value, discusses the potential gap in care that may occur with the end of the Oncology Care Model.
With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?
November 22nd 2021

With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?

Gianna Melillo
The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.
clipart images of an apple, pill bottle, healthcare forms, doctors, hand holding a heart, piggy bank with a calculator, and a stack of money
November 20th 2021

US Oncology Network, Tennessee Oncology Tout Medicare OCM Savings

Skylar Jeremias
A report from the Centers for Medicare and Medicaid Innovation confirmed that practices within the US Oncology Network and Tennessee Oncology participating in the Oncology Care Model (OCM) program have contributed significant savings to the agency.
Funmi Olopade, MD
November 20th 2021

Dr Funmi Olopade: Breast Cancer Screening Is Not One Size Fits All

Hayden E. Klein
Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how different populations are at different risk for breast cancer and the importance of informed screening.
Matt Dickson
November 7th 2021

Contributor: Don’t Delay—Why Now Is the Time to Reengage Patients in Routine Cancer Screenings

Matt Dickson
Ignoring life-threatening, non–COVID-19 conditions for too long can turn one health crisis into another. Now is the time to resume cancer screenings, like mammograms and colonoscopies, because early detection can be lifesaving.
Cells being irradiated
October 3rd 2021

Consolidative Radiation Therapy Improves Progression-Free Survival in DLBCL

Deanna Ferreri, PhD
This new study shows that consolidative radiation therapy may be of benefit to persons with diffuse large B-cell lymphoma, both bulky and nonbulky disease.
Dr Marcus Neubauer Outlines the Benefits of the OCM and the Potential Successor Model
October 1st 2021

Dr Marcus Neubauer Outlines the Benefits of the OCM and the Potential Successor Model

The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
Elizabeth Kwo, MD, MBA, MPH, deputy chief clinical officer at Anthem BCBS, a
September 29th 2021

Dr Elizabeth Kwo on Using Predictive Analytics to Curb Avoidable Hospitalizations During Cancer Therapy

Anemia, fevers, dehydration, and other side effects from cancer treatment are all candidates for targeting with predictive analytics in an effort to care for patients are home instead of the hospital, said Elizabeth Kwo, MD, MBA, MPH, the deputy chief clinical officer at Anthem BCBS, and a speaker at the 10th anniversary of Patient-Centered Oncology Care® conference.
Advances in Understanding of DLBCL Offer Prognostic and Theraptic Value
September 26th 2021

Surface Proteins in DLBCL Offer Therapeutic Targets

Deana Ferreri, PhD
Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.
Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status
September 19th 2021

Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status

Mary Caffrey
Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.
In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1
September 19th 2021

In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1

Mary Caffrey
The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”
<1
...
121314151617181920
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo